Form 4: Omega Healthcare Investors Director Acquires Shares as Part of Compensation Package

Lisa Egbuonu-Davis, a director at Omega Healthcare Investors, acquired 4,605 shares of common stock as part of her director compensation, vesting approximately one year from the grant date.

Summary

• Lisa Egbuonu-Davis, a director of Omega Healthcare Investors Inc., acquired 4,605 shares of common stock on June 7, 2024.
• The acquisition was part of her director compensation, granted via a Restricted Stock Grant Award Agreement.
• The shares were acquired at a price of $32.57 per share.
• These shares will vest approximately one year from the grant date, specifically at the Company's 2025 Annual Meeting of Shareholders.
• Following the transaction, Egbuonu-Davis directly owns 18,118 shares of Omega Healthcare Investors Inc.
• Egbuonu-Davis has granted power of attorney to Robert O. Stephenson, Gail D. Makode, Thomas H. Peterson and Meghan C. Lyons to handle SEC filings related to her transactions in company securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard director compensation practices and aligns director interests with shareholders.

Positives

• Director receiving stock as part of compensation aligns interests with shareholders.
• The vesting period encourages long-term commitment from the director.

Future Outlook

The restricted stock will vest at the Company's 2025 Annual Meeting of Shareholders, approximately one year from the grant date.

Industry Context

Director stock ownership is common in the healthcare REIT sector to align management and shareholder interests. This transaction is a routine part of director compensation.

Comparison to Industry Standards

• Director compensation packages often include stock grants in REITs like Welltower (WELL), Ventas (VTR), and Healthpeak Properties (PEAK).
• The vesting schedule of approximately one year is typical for restricted stock grants to directors.
• The size of the stock grant is within the range of what is commonly seen for directors in similarly sized healthcare REITs.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning her interests with those of shareholders.
• Employees and other stakeholders are unlikely to be directly impacted by this transaction.

Next Steps

• The restricted stock will vest at the Company's 2025 Annual Meeting of Shareholders.

Key Dates